Not currently recruiting at University of California Health
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA UCSF
- Dates
- study startedcompletion around
- Principal Investigator
- by Aaron Lisberg, MD (ucla)

Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Aaron Lisberg, MD (ucla)
HS Assistant Clinical Professor, Medicine
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Daiichi Sankyo
- ID
- NCT06203210
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 540 study participants
- Last Updated